Peptavo is Accredited for 20 CME hours.Peptavo is Jointly Accredited for 20 CME hours. Learn more about accreditation
Peptavo is Accredited for 20 CME hours.Peptavo is Jointly Accredited for 20 CME hours. Learn more about accreditation
Get volume discounts if you are getting 3 or more clinicians certified
Book a Call
Many peptides are legal in the US. Whether a specific one is depends on how it reaches the patient: as an FDA-approved drug, a compounded prescription, a supplement, or a vial sold for research use only. Here is how each pathway works, what changed in 2026, and what Florida, California, and Texas add.
Yes. Peptides are legal in the United States when they reach the patient as an FDA-approved drug on a prescription, or as a compounded prescription from a licensed pharmacy whose bulk ingredient qualifies under federal law or is one of six peptides covered by an October 2026 HHS enforcement policy. Collagen-type peptides taken by mouth are legal as supplements. Peptides sold online as "research use only" are not legal to sell or use as drugs for people, whatever the label says.
The word "peptide" covers insulin, semaglutide, collagen in a protein shake, and unlabeled vials from a website. Federal law treats each of those differently, so the useful question is which pathway a given product uses. This guide covers each pathway, the controlled substance question, the 2026 FDA developments behind headlines about peptides "being legalized," and the state rules people search for most.
Status as of November 6, 2026. On October 30, 2026, HHS published a draft policy, open for comment until November 13, saying it will not take enforcement action against 503A pharmacies and physicians that compound six peptides under ten conditions while FDA rulemaking proceeds. FDA has not published a proposed rule, and none of those substances appears on the final list at 21 CFR 216.23. Our peptide regulation tracker records each change as it happens.
| How the peptide reaches the patient | Legal for human use? | What governs it |
|---|---|---|
| FDA-approved peptide drug | Yes, with a valid prescription | FDA approval and labeling; off-label use is within the practice of medicine |
| Compounded by a 503A pharmacy | Yes, when the bulk substance qualifies and the prescription names an individual patient | Section 503A of the FD&C Act and state pharmacy law |
| Compounded by a 503B outsourcing facility | Yes, within the facility's conditions | Section 503B, FDA registration, and current good manufacturing practice |
| Sold as "research use only" | No | The FD&C Act's drug provisions, enforced through FDA warning letters |
| Dietary supplement taken by mouth | Yes, when the ingredient is a lawful dietary ingredient | DSHEA and FDA's supplement rules |
| Topical cosmetic | Yes, when the product makes no drug claims | The FD&C Act's cosmetic provisions |
No official federal list of "legal peptides" exists. Legality attaches to a product, a source, and an intended use, so two vials of the same molecule can sit on opposite sides of the line.
No, peptides are not illegal as a class. No federal law bans peptides, and none is on a DEA schedule. What is illegal is a particular way of making, selling, or using one.
Four situations cross the line. Selling a peptide as a drug for people without FDA approval or a compounding exemption is illegal, and that covers the research use only market. A pharmacy that compounds from a bulk substance that does not qualify under Section 503A or 503B is outside federal law, which is why Category 2 peptides largely disappeared from 503A pharmacies after 2023. Six peptides now sit under an HHS enforcement policy that covers compounding meeting its conditions, described below. Distributing growth hormone for any use FDA has not authorized is a federal felony. And a pharmacy or clinician can break state law while clearing federal law, for example by shipping into a state without a nonresident license or prescribing without the examination the state requires.
Possessing a peptide for your own use is not a federal crime in itself, because peptides are not controlled substances. Federal enforcement aims at the people who sell unapproved peptides, mostly through FDA warning letters, and the risk a buyer carries is the quality of an untested product. Tested athletes are a separate case: peptide hormones are banned in sport even where they are legal to prescribe.
The six peptides patients ask about most, as of November 4, 2026:
| Peptide | FDA status | Can a pharmacy compound it? | Legal to prescribe? |
|---|---|---|---|
| Semaglutide | Approved as Ozempic, Rybelsus, and Wegovy | Only narrowly. The shortage ended in February 2025, so a 503A pharmacy may not regularly make copies of the approved drug, and in April 2026 FDA proposed keeping it off the 503B bulks list | Yes, the approved products. A compounded version needs a documented, patient-specific reason the approved drug will not work |
| Tirzepatide | Approved as Mounjaro and Zepbound | Same limits as semaglutide. The shortage ended in December 2024 | Same as semaglutide |
| Retatrutide | Investigational. Lilly plans to submit it to FDA in the first quarter of 2027 | No. It has no monograph, is not part of an approved drug, and is not on the Bulks List | Only inside a clinical trial or Lilly's expanded access program. FDA sent warning letters to online sellers of it in 2026 |
| Insulin | Approved, and regulated as a biologic since March 2020 | No. Biologics fall outside both 503A and 503B | Yes. Older human insulins (regular and NPH) are also sold without a prescription |
| BPC-157 | Not approved | Under HHS enforcement discretion since October 30, 2026: a 503A pharmacy may compound the acetate form for subcutaneous, intramuscular, oral, or topical use when it meets the policy's ten conditions. It is not on the Bulks List |
Any row can change with a single FDA notice. Check the date above and FDA's current category list before relying on it.
The clearest legal ground is an FDA-approved drug. Peptide medicines have been part of ordinary practice for decades: insulin, oxytocin, leuprolide, octreotide, teriparatide, and the GLP-1 receptor agonists semaglutide, liraglutide, and tirzepatide are all peptide or peptide-based drugs with FDA approval for specific indications.
A licensed prescriber may prescribe an approved peptide drug for its labeled indication and, in most cases, off label. FDA regulates how drugs are marketed, and the decision to use an approved drug for an unapproved indication belongs to the practice of medicine. Off-label prescribing still carries the ordinary duties of informed consent, documentation, and a standard of care the clinician can defend.
There is one important exception, covered in the controlled substance section below: growth hormone.
Compounding is the second legal pathway, and the one where most of the confusion sits. A compounded drug is prepared by a pharmacy for a patient whose needs an approved product does not meet. Compounded drugs are not FDA-approved, and FDA does not review them for safety or effectiveness before they are dispensed.
Under Section 503A, a state-licensed pharmacy or physician may compound for an identified patient on a valid prescription. When the pharmacy starts from a bulk drug substance, that substance has to meet one of three conditions: it is covered by a USP or NF monograph, it is a component of an FDA-approved drug, or it appears on the 503A Bulks List. A 503A pharmacy also may not regularly compound what are essentially copies of a commercially available drug. That rule is why compounded semaglutide and tirzepatide largely left the market after FDA declared their shortages resolved in February 2025 and December 2024.
Section 503B covers outsourcing facilities. These register with FDA, follow current good manufacturing practice, and may supply office stock without a patient-specific prescription. They work from their own bulks list and from FDA's drug shortage list.
For substances nominated to the 503A Bulks List but not yet decided, FDA has used interim categories. Category 1 substances are under evaluation, and FDA has generally not taken action against pharmacies that compound with them while other conditions are met. Category 2 substances raised significant safety concerns in FDA's view. In 2023, FDA placed a group of popular peptides in Category 2, which effectively stopped 503A pharmacies from compounding them.
On April 15, 2026, FDA removed 12 peptides from Category 2 after their nominations were withdrawn. Removal did not move them to Category 1 or onto the Bulks List. Law firms advising pharmacies described these substances as sitting in a gray zone, with real enforcement risk for any pharmacy that treated removal as permission to compound.
On October 30, 2026, HHS moved six of the twelve out of that gray zone. Its enforcement discretion policy says HHS will not act against 503A pharmacies and physicians compounding BPC-157, TB-500, epitalon, MOTS-c, KPV, or semax, each in one form and set routes, when the product meets ten conditions: a registered manufacturer named on the certificate of analysis, a single active ingredient, adverse event reporting to FDA and the states, and a patient-specific prescription among them. The other six, injectable GHK-Cu, LL-37, dihexa, melanotan II, PEG-MGF, and emideltide, remain without interim protection. The policy excludes 503B outsourcing facilities, binds no state board, and can be withdrawn without notice. The regulation tracker lists every condition.
The categories are an enforcement policy that FDA can revise at any time. Check the current FDA bulk substances page for a specific substance before relying on any secondhand list, including ours.
A large online market sells peptides labeled "research use only" or "not for human consumption." Selling these products for use in people violates federal drug law, and the label does not change that. FDA decides what a product is intended for from the whole context: dosing guidance, before-and-after claims, syringes sold alongside, and how the seller talks to buyers.
FDA has said this directly. In a March 31, 2026 warning letter to one seller, the agency wrote that despite "Research Use Only" and "not intended for human consumption" statements on the labeling, "evidence obtained from your website establishes that your products are intended to be drugs for human use." It cited the products as unapproved new drugs. FDA published a set of these letters in April 2026 and sent five more on August 24, 2026, all to online peptide sellers.
For clinicians, the consequence is simple. A research use only product cannot be prescribed, dispensed, or administered to a patient. When a patient is already using one, record it as a self-sourced exposure of unknown identity, purity, and sterility, and keep treating the underlying problem. Federal drug law is aimed mainly at the people who sell these products, which is why the warning letters go to sellers, but the patient bears the quality risk.
Collagen peptides in a powder or capsule are a lawful food or dietary supplement. The supplement pathway has two limits that rule out most of what people mean by "peptide therapy."
First, a supplement must be intended for ingestion. An injectable product cannot be a dietary supplement. Second, the statutory definition excludes an ingredient that was approved as a drug, or studied as a drug in substantial public clinical investigations, before it was sold as a food or supplement. Several popular peptides fall on the drug side of that line.
Topical peptides in skin care are generally regulated as cosmetics. A cosmetic that claims to treat a condition or change the structure or function of the body becomes a drug in FDA's eyes.
Generally, no. Peptides are not scheduled under the federal Controlled Substances Act, and there is no DEA schedule for them. That is also why the Ryan Haight Act's in-person exam rule for prescribing controlled substances by telehealth does not apply to most peptides. State telehealth law still does.
Growth hormone is the exception that matters. It is a protein hormone, often grouped with peptides in conversation, and it is not on a DEA schedule either. But 21 U.S.C. 333(e) makes it a felony to distribute growth hormone, or possess it with intent to distribute, for any use in people other than treating a disease or recognized condition that FDA has authorized and a physician has ordered. Off-label prescribing, which is routine for most drugs, is a federal crime for growth hormone.
Athletes face a separate rule. The World Anti-Doping Agency prohibited list bans peptide hormones, growth factors, and related substances at all times. A peptide can be legal to prescribe and still end a tested athlete's eligibility.
Headlines about peptides "being legalized" refer to the July 23 and 24, 2026 meeting of FDA's Pharmacy Compounding Advisory Committee. The committee voted to recommend six of seven peptide families it reviewed for the 503A Bulks List, against the recommendation of FDA staff. Our breakdown of that meeting covers each vote.
The vote is advisory. Adding a substance to the Bulks List takes notice-and-comment rulemaking: a proposed rule, a public comment period, and a final rule. As of this update FDA has published no proposed rule, and it is not required to follow the committee. FDA has said the committee will consider more peptides at a meeting expected by February 2027.
The closest step so far came from HHS on October 30, 2026, when it published an enforcement discretion policy for those six peptides while FDA rulemaking proceeds. It changes no statute or regulation, covers only 503A compounding that meets its conditions, and HHS can withdraw it.
Listing would also make these peptides eligible for compounding only. It would not make them FDA-approved drugs, and it would not make research use only vials legal.
A state cannot make legal what federal law prohibits, but every state adds its own rules. Those rules cover who may prescribe, what counts as a valid patient relationship, how telehealth works, which pharmacies may ship into the state, and how medical spas operate. A product that clears federal law can still be prescribed or dispensed unlawfully under state law.
Florida has no peptide-specific statute. Peptide prescribing falls under the Florida Board of Medicine's general standards, and compounding falls under the Board of Pharmacy's rules, which follow the federal 503A and 503B framework. An out-of-state clinician treating Florida patients by telehealth must register under section 456.47 of the Florida Statutes, and a pharmacy shipping into Florida needs a nonresident pharmacy registration, plus a separate nonresident sterile compounding permit for injectables. A 2026 bill on compounded weight-loss drugs, SB 860, died in committee.
California's medical board treats prescribing without an appropriate prior examination and a medical indication as unprofessional conduct under Business and Professions Code section 2242. That standard applies to peptides as it does to any prescription drug, and the examination can occur by telehealth when the standard of care allows. Pharmacies outside California need a nonresident pharmacy license, and a separate nonresident sterile compounding license to ship injectables in. California's ban on the corporate practice of medicine also shapes how a clinic or med spa offering peptides may be owned.
In Texas, physicians who delegate prescribing to nurse practitioners or physician assistants do so under the Texas Medical Board's delegation rules in Chapter 157 of the Occupations Code. Texas House Bill 3749, effective September 1, 2025, regulates elective IV therapy outside physician offices and licensed facilities, which reaches many med spas that also offer peptides. Out-of-state pharmacies need a Texas nonresident pharmacy license to dispense to Texas patients.
State activity is accelerating. Indiana enacted Senate Bill 282 in March 2026, which requires medical spas to register with the state's Medical Licensing Board starting January 1, 2027 and to report serious adverse events. Expect more states to regulate med spas, IV therapy, and compounded drugs in 2027 sessions.
Each prescription needs five questions answered, in this order.
Documented training supports that record. Peptide CME from an accredited provider shows a board the clinical and regulatory grounding behind each prescription. Peptavo's peptide course for physicians and course for nurses and nurse practitioners teach the compounding categories, 503A pharmacy vetting, and the risk of research use only sources as part of 20 accredited hours.
It is legal to fill a valid prescription through a licensed online pharmacy. Buying research use only peptides for personal injection sits outside every lawful pathway: the sellers are violating federal drug law, and FDA's warning letters target them for it. A buyer receives a product with no assurance of identity, purity, or sterility.
Usually, within their state's scope of practice rules. Approved and compounded peptides are prescription drugs, so the same authority that lets an NP or PA prescribe other prescription drugs applies, along with any supervision or collaboration agreement the state requires. The state-by-state detail is in our guides for nurse practitioners and physician assistants.
Four things: FDA removed 12 peptides from Category 2 in April without adding them to the Bulks List, its advisory committee recommended six peptide families for the Bulks List in July, FDA kept issuing warning letters to research use only sellers, and on October 30 HHS published an enforcement discretion policy letting 503A pharmacies compound those six peptides under ten conditions. None of the six is on the Bulks List or FDA-approved.
| Only from a 503A pharmacy meeting those conditions, on a patient-specific prescription, where state law allows. Research use only vials remain illegal to sell for human use. Banned in tested sport |
| GHK-Cu | Not approved as a drug | Topical and other non-injectable forms are in Category 1, so 503A pharmacies may compound them under FDA's interim policy. Injectable GHK-Cu has no category and goes to the advisory committee by February 2027 | Topical, yes, including cosmetics that make no drug claims. Injectable GHK-Cu falls outside the HHS policy and has no interim protection |
